Genmab Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Genmab yıllık ortalama 16.1% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 13.2% annual. Gelirler growing yılda ortalama 27% oranında artmaktadır. Genmab'in özkaynak karlılığı 16.8% ve net marjı 30.7%'dir.

Anahtar bilgiler

16.1%

Kazanç büyüme oranı

15.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	12.9%
Gelir büyüme oranı	27.0%
Özkaynak getirisi	16.8%
Net Marj	30.7%
Sonraki Kazanç Güncellemesi	08 Aug 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Genmab nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BMV:GMAB N Gelir, gider ve kazançlar (DKK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 24	17,783	5,467	3,478	8,189
31 Dec 23	16,474	4,352	3,297	7,630
30 Sep 23	17,023	4,296	3,284	7,285
30 Jun 23	16,366	4,749	3,115	6,683
31 Mar 23	15,330	5,283	2,900	6,112
31 Dec 22	14,505	5,452	2,676	5,524
30 Sep 22	11,987	5,654	2,267	5,219
30 Jun 22	10,210	3,962	1,903	4,847
31 Mar 22	9,020	2,377	1,534	4,486
31 Dec 21	8,417	2,957	1,283	4,181
30 Sep 21	7,907	2,873	1,002	3,787
30 Jun 21	7,321	2,513	841	3,394
31 Mar 21	10,800	5,585	756	3,248
31 Dec 20	10,111	4,758	661	3,137
30 Sep 20	11,028	5,649	546	2,880
30 Jun 20	10,344	5,656	483	2,766
31 Mar 20	5,667	2,363	377	2,555
31 Dec 19	5,366	2,166	342	2,386
30 Sep 19	3,641	1,528	285	2,173
30 Jun 19	3,199	1,170	258	1,910
31 Mar 19	2,935	1,345	241	1,664
31 Dec 18	3,025	1,472	214	1,431
30 Sep 18	2,807	1,424	195	1,227
30 Jun 18	2,532	1,239	177	1,112
31 Mar 18	2,796	1,286	157	995
31 Dec 17	2,365	1,104	147	852
30 Sep 17	2,275	1,159	131	795
30 Jun 17	2,316	1,354	121	718
31 Mar 17	1,897	1,215	110	704
31 Dec 16	1,816	1,187	102	661
30 Sep 16	1,463	735	101	642
30 Jun 16	1,376	686	94	606
31 Mar 16	1,196	535	93	529
31 Dec 15	1,133	764	91	488
30 Sep 15	774	443	92	443
30 Jun 15	768	463	90	441
31 Mar 15	710	420	86	459
31 Dec 14	850	301	80	506
30 Sep 14	851	292	77	517
30 Jun 14	729	138	72	534
31 Mar 14	751	138	69	545
31 Dec 13	664	70	67	528
30 Sep 13	611	-5	64	539
30 Jun 13	577	-55	65	535

Kaliteli Kazançlar: GMAB N yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: GMAB N 'nin mevcut net kar marjları (30.7%) geçen yılın (34.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: GMAB N şirketinin kazancı son 5 yılda yılda 16.1% oranında arttı.

Büyüme Hızlandırma: GMAB N 'un son bir yıldaki kazanç büyümesi ( 3.5% ) 5 yıllık ortalamasının ( 16.1% /yıl) altındadır.

Kazançlar vs. Sektör: GMAB N geçen yılki kazanç büyümesi ( 3.5% ) Biotechs sektörünün 3.7% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: GMAB N 'nin Özsermaye Getirisi ( 16.8% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/06/24 12:17
Gün Sonu Hisse Fiyatı	2024/03/27 00:00
Kazançlar	2024/03/31
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Genmab A/S 45 Bu analistlerden 25, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andrew Carlsen	ABG Sundal Collier
Armelle Moulin	AlphaValue
Emily Field	Barclays

Genmab Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold Mex$55m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 18%

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Co-Founder recently sold Mex$161m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Investor sentiment deteriorated over the past week

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022